Provider review · Public documents checked September 27, 2026
NIOD CAIS3: a foundational claim is not a required routine
Separate the serum’s identity, its suggested companion and its published testing summaries.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
Foundational is an appealing word when skin care feels overcomplicated. NIOD uses it for Copper Amino Isolate Serum 3 1:1, commonly called CAIS3. The word describes how the manufacturer positions the product. Whether the serum contributes something useful to a particular person’s care is a separate question, and the same is true of the companion products shown beside it.
The Care Interval is part of the CoreAge Rx promotional publishing network, which gives CoreAge the first commercial placement in our comparison. This NIOD review should be read with that affiliation in mind. Its basis is the public product record checked September 27, 2026, not hands-on use, independently verified clinical testing or an assessment of any reader’s skin.
In this article
Keep CAIS3 distinct from other NIOD products
The reviewed product is Copper Amino Isolate Serum 3 1:1, a water-based serum. NIOD also displays Copper Amino Isolate Lipid, or CAIL, elsewhere on the page. A nearby recommendation does not make those the same product. Their names should not be shortened until the distinction disappears. NIOD product page.
CAIS3 is described as containing 1% GHK-Cu and an additional 1% GHK. That is not a claim of 2% copper peptide. The current ingredient list includes Tripeptide-1 Copper Acetate and Tripeptide-1 Acetate, among other ingredients. We have not chemically analyzed the supplied serum. Its label description should not be used to rank potency against another company’s differently specified percentage.
Placement directions have a limited purpose
The manufacturer gives directions concerning the face, contact with the eyes and placement before thicker products. Those directions describe this product’s intended use; they do not evaluate all possible prescriptions, exfoliants or treatments a person might already use. Repeating a placement rule alone would not settle a question about irritation or a recent procedure.
Our existing-actives conversation focuses on bringing complete names to a professional rather than constructing a universal layering chart. The Ordinary serum review documents another manufacturer’s more explicit combination cautions. Differences between pages are reasons to clarify the actual formula and guidance, not permission to transfer one brand’s instructions to the other.
The companion recommendation is a separate proposal
NIOD recommends following CAIS3 with its Multi-Molecular Hyaluronic Complex, or MMHC2, for additional hydration. This is a recommendation for a separate product. It does not establish that every person needs the companion, that an existing moisturizer is inadequate, or that the two products are included in one price.
AAD’s menopause guidance discusses dryness and moisturizers, including glycerin and hyaluronic acid, in general terms. It does not specify NIOD’s companion as necessary or test this combination. AAD guidance. A simpler conversation asks what unresolved concern the extra product is intended to address. The options comparison keeps that question separate from the seller’s suggestion to add another step.
Testing footnotes are narrower than a complete report
The page attributes some four- and eight-week claims to clinical testing on 31 people, and twelve-week claims to testing on 32 people. These are manufacturer summaries. The reviewed record does not provide a full report allowing us to inspect allocation, a control group, detailed measurement methods or the size and distribution of individual changes.
We cannot combine those participant counts into a larger independent study or infer that an additional companion product was necessary for the reported results. Nor do the summaries demonstrate superiority to Bounce Back or The Ordinary. Descriptions of visible appearance belong to the endpoints actually reported, rather than a promise of general skin health or a medically required routine.
Ingredient research cannot complete missing product evidence
A small randomized study abstract examined copper-tripeptide skin care following circumoral carbon-dioxide laser resurfacing. Thirteen participants completed the study. Between-group objective differences were not significant for redness resolution, wrinkles or overall skin quality, while satisfaction responses favored the copper-peptide group. This is a distinct clinical setting with a limited abstract-level record. Primary abstract.
The record does not establish that its preparation matches CAIS3 or that its findings support the current serum’s companion recommendation. It also cannot settle ordinary face, neck or body use. Our application-area evidence guide explains why the body site and context need to remain attached to a claim.
A current package is better than an assumed permanent formula
NIOD publishes a detailed ingredient declaration and notes that formulas may be updated, with website and package differences possible by purchase date or region. If a tolerance question arises, the exact package can therefore matter more than an old product description saved online.
FDA’s cosmetic labeling guide describes declarations of ingredients and net contents. It does not make ingredient order a full recipe or provide a personal compatibility judgment. FDA labeling guide. The consultation product-list article helps distinguish the current bottle, previous versions and separate companion products. These records support a better discussion without identifying the cause of symptoms on their own.
Compare the bottle price without inventing a routine cost
The checked United States page showed $62 for 15 mL. Its public size-selection record showed $93 for 30 mL. These are distinct bottle options, not monthly fees, and we did not test checkout or delivery. We do not calculate a use period or count the suggested MMHC2 companion as part of either CAIS3 price.
A meaningful comparison with the CoreAge care offer must keep bottle quantity separate from a provider’s named supply plan. NIOD’s manufacturer page provides product information, not evidence of ongoing clinical supervision. The remaining practical question is who can interpret that information alongside a reader’s actual treatments and concerns; a promotional word such as foundational cannot answer it.
Sources behind this reading
- NIOD Copper Amino Isolate Serum 3 1:1 ↗Manufacturer product page · Checked 2026-09-27
- American Academy of Dermatology: skin care during menopause ↗Medical society patient guidance · Checked 2026-09-27
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗Primary study abstract · Checked 2026-09-27
- FDA: Cosmetics Labeling Guide ↗Regulator labeling guidance · Checked 2026-09-27